eli lilly glp-1 drugs Gets Speedy FDA Nod for Oral Drug, a Competitor to New Novo Nordisk Pill Lilly launches GLP-1 pill, kicking

Clinical Take-Home Messages GLP-1RAs are no longer diabetes-only drugs. They are becoming: Obesity therapies Cardiovascular protective agents Anti-inflammatory therapies Neuroprotective candidates Metabolic disease modifiers Conclusion We are witnessing a historic transition in medicine

This is significant because it is the natural site of action of the GLP1-RAs and most relevant to their uses in diabetes and appetite control

There was literally no desire to eat anything, said Zarghami

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

References Min T, Bain SC

The drug had to be injected twice a day, which had to be done within 15-30 minutes before breakfast and dinner